A major international study has found that obesity-related cancers are rising sharply among both younger and older adults, challenging long-held beliefs about which age groups are most at risk.

A genetic mutation that causes severe obesity may paradoxically protect against heart disease, according to new research published in Nature Medicine.

New research from the University of Oxford has revealed that the NHS spends an estimated £340 million each year on healthcare linked to weight-related problems in children – and it is not just obesity that is driving the cost. The study found that underweight children require a similar level of medical support to those who are living with severe obesity, challenging common assumptions about childhood health priorities.

A new study has shown that artificial intelligence (AI) and computer vision can accurately detect and monitor unhealthy food marketing aimed at children, offering a faster and more efficient way to track potentially harmful advertising practices.

A new study has shown that the weight-loss drug tirzepatide significantly improves health outcomes in people with obesity and heart failure, even when type 2 diabetes limits the extent of weight loss.

Obesity at the age of 20 may independently predict the development of postpartum impaired glucose tolerance (IGT) and diabetes in women with a history of gestational diabetes mellitus (GDM), according to new research published in Diabetes Research and Clinical Practice.

The World Health Organization (WHO) has called on governments to widen the scope of food taxes to target overall nutritional quality, arguing that broader measures could reduce obesity, improve public health and support environmental sustainability.

The Welsh Government has been told it must act urgently to tackle Wales’ growing obesity crisis, as new figures reveal that a quarter of children are overweight or obese by the time they start school.

A new weight-loss drug that works by reprogramming how the body processes fat has entered human trials, raising hopes of a long-term solution to obesity.

A new study has raised concerns about the growing use of prescription weight-loss drugs, linking them to disordered eating and mental health problems among young males.

The OASIS 4 phase three trial has confirmed the safety and effectiveness of once-daily oral semaglutide 25 mg for weight management in adults with overweight or obesity.

New research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) shows that some individuals who are taking Ozempic, Wegovy or Mounjaro find that foods taste sweeter or saltier than before.

New research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) shows that individuals who are taking semaglutide for weight loss experience less food noise than before.

Elderly people who experience fluctuations in weight or body composition may face a significantly faster decline in cognitive ability, according to new research.

A new study has found that half of adults without diabetes who begin taking the weight-loss drug semaglutide in Denmark stop treatment within a year.

Tripling the standard dose of semaglutide, a popular drug prescribed to treat obesity, led to significantly greater weight loss and associated metabolic benefits without increased risk of serious side effects, a multicentre clinical trial led by a UT Southwestern Medical Center researcher shows.

Professor Melanie Davies, Chair of the Obesity & Weight Management Alliance, presented the latest findings from the REDEFINE 2 study at the prestigious European Association for the Study of Diabetes (EASD) 2025 meeting.

New research presented at the Annual Meeting of the European Association for the Study of Diabetes 2025 shows that daily treatment with the new once-daily GLP-1 agonist orforglipron results in substantial weight loss in people living with obesity that do not have type 2 diabetes.

In adults living with type 1 diabetes and obesity, low dose tirzepatide reduced their weight, HbA1c levels and insulin dose requirements, a clinical trial has demonstrated.

Being overweight does not necessarily increase the risk of an early death, new research suggests.